Skip to main content

Table 2 Virologic, serologic and biochemical response at week 48

From: Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients

 

Baseline

Week 24

Week 48

Total

P

Mean HBV DNA (log10 IU/mL)

6.61

1.72

1.49

5.12↓

0.559

 ETV (n = 105)

6.56

1.80

1.55

5.01↓

 

 TDF (n = 105)

6.66

1.64

1.44

5.22↓

 

HBV DNA negativity by PCR

   

161(76.7%)

0.192

 ETV (n = 105)

 

58 (55.2%)

76 (72.4%)

  

 TDF (n = 105)

 

56 (53.3%)

85 (81.0%)

  

HBeAg loss/seroconversion

   

18 (14.9%)

0.452

 ETV (n = 58)

  

7 (12.1%)

  

 TDF (n = 63)

  

11 (17.5%)

  

Biochemical response

   

150 (81.5%)

0.647

 ETV (n = 92)

  

77 (83.7%)

  

 TDF (n = 92)

  

73 (79.3%)

  
  1. Data are expressed mean or number
  2. ETV entecavir, HBeAg hepatitis B e antigen, HBV hepatitis B virus, TDF tenofovir